louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03892343: Effects of Renal Transplantation on Uraemic Cardiomyopathy
Official title: A Prospective Study of the Effects of Renal Transplantation on Uraemic Cardiomyopathy Using Magnetic Resonance Imaging.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cardiomyopathies
Lead sponsor: University Hospital Birmingham NHS Foundation Trust
Sponsor class: OTHER
First posted: 2019-03-27
Enrollment: 100
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will comprise of patients with end-stage renal failure currently awaiting either live or deceased donor transplantation.

Brief summary: Chronic kidney disease (CKD) is associated with a high risk of death and morbidity due to cardiovascular disease. Much of this is caused by left ventricular disease characterised by abnormal muscle thickness and scaring. This process appears to start early in the course of CKD and causes heart failure and dangerous abnormal heart rhythms. Previous work suggests that the process may be reversible by kidney transplantation but almost all of the studies are small, retrospective and lack scientific rigour. Furthermore, they almost all use echocardiography, which is inaccurate in patients with CKD. The investigators plan to perform the first large, prospective, controlled, blind-analysed study using cardiac magnetic resonance imaging to determine whether CKD associated cardiomyopathy is reversed by kidney transplantation and if so, whether factors such as blood pressure and mediators of metabolic bone disease/fibrosis are important in effecting this change. Greater understanding of the mechanisms responsible for CKD associated cardiomyopathy could lead to future strategies and treatments to improve the high cardiovascular mortality associated with this condition.


Eligibility criteria: Inclusion Criteria:

1. Patients registered on the kidney transplant waiting list at the University Hospital Birmingham NHS Foundation Trust.
2. Ages over 18 years

Exclusion Criteria

1. Non-standard anti-rejection treatment, post transplant.
2. Previous history of being unable to tolerate MRI scanner.
3. Contraindication to MRI - eg metal fragments in ey

Primary outcomes:
measure: Left Ventricular Mass
timeFrame: One year.
Secondary outcomes:
measure: Native Myocardial T1 Times.
timeFrame: One year.
measure: Blood Pressure
timeFrame: One year.
measure: Pulse Wave Analysis.
timeFrame: One Year
Other outcomes:
Locations:
city: Birmingham
country: United Kingdom
facility: Queen Elizabeth Hospital
state: West Midlands
Study officials:
affiliation: University Hospital Birmingham NHS Foundation Trust
name: Charles Ferro, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05717543: Imaging of Corneal and Crystalline by Near Infrared Retro-illumination
Official title: Imaging of Corneal and Crystalline by Near Infrared Retro-illumination
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Eye Diseases
Keywords: pigmentary glaucoma
crystalline pathology
corneal pathology
Retroillumination
Infrared
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2023-02-08
Enrollment: 384
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Exploratory pilot study
Primary purpose: DIAGNOSTIC

Brief summary: Retroillumination photography is difficult. The reflections on the cornea and the lens are constant and prevent from obtaining a complete and clear image. Study team have modified a slit lamp intended to photograph the anterior segment of the eye in retroillumination by using a light source in the near infrared (780 nm), and a process which eliminates the reflections.


Eligibility criteria: Inclusion Criteria:

* Patient with corneal pathology, crystalline pathology, or pigmentary glaucoma with transilluminable iris. In case of bilateral disease, both eyes will be photographed
* Patient having received an instillation of eye drops to dilate the pupil of the eye to be photographed (or of both eyes).

Exclusion Criteria:

* Major blepharospasm
* Poor or no pupillary dilation: patient with allergy or intolerance to eye drops used for pupillary dilation, refusal of pupillary dilation
* Pregnant or breastfeeding patient
* Person under legal protection

Primary outcomes:
measure: Percentage of pictures without reflection (%)
timeFrame: Year: 1
Secondary outcomes:
measure: Percentage of pictures clean on the pathological area (%)
timeFrame: Year: 1
measure: Serious adverse events
timeFrame: Year: 1
Other outcomes:
Locations:
city: Saint-Étienne
country: France
facility: CHU Saint-Etienne
Study officials:
affiliation: CHU SAINT-ETIENNE
name: Gilles THURET, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00018343: Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen
Official title: Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Alzheimer's Disease
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2001-07-05
Sex: FEMALE
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the potential beneficial effects of estrogen on cognitive function of women with Alzheimer's Disease.


Eligibility criteria: * Post menopausal women with alzheimer's disease
* free of any major medical or neurological disease,
* medically safe to be treated with estrogen.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Lakewood
country: United States
facility: VA Puget Sound Health Care System
state: Washington
Study officials:
name: Suzanne Craft, Ph.D
name: Laura Baker, Ph.D
name: Murray Raskind, M.D.
References:
Clinical trial NCT06783543: Efficacy of Home-based Treatment for Breast Cancer-related Lymphedema
Official title: Efficacy of Home-based Treatment for Breast Cancer-related Lymphedema
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Lymphedema Arm
Keywords: lymphedema
breast cancer
Manual therapy
home-based therapy
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2025-01-20
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: According to the computer random number method, the enrolled patients were divided into home treatment group and outpatient treatment group, 20 cases each.
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trials is to explore the effectiveness of home-based iymphedema treatment and the differences between the home-based and outpatient treatment. The main question is to verify that home-based treatment is as effective as outpatient treatment. We set two groups in this study, comparing the volume of affected upper limb to see if home-based iymphedema treatment is valuable method.

Detailed description: Secondary outcome measures:

1. Core Quality of Life Questionnaire (EORTC QLQ-C30), It included five functional measures (somatic function, role function, cognitive function, emotional function, social function), three symptom measures (fatigue, pain, nausea and vomiting), six individual measures (dysphagia, loss of appetite, sleep disturbance, constipation, diarrhea, financial hardship), and one patient self-assessment item (total health status).
2. Breast Cancer and Lymphedema Symptom Experience Index (BCLE-SEI).

Eligibility criteria: Inclusion Criteria:

1. Lymphedema appeared in the upper limb after breast cancer-related treatment, and compared with the healthy side, the edema dimension was more than 2cm.
2. Age 18-75 years old;
3. Edema stage Ⅰ to Ⅱ;

Exclusion Criteria:

1. People with severe cognitive impairment;
2. Bilateral lymphedema;
3. Patients undergoing radiotherapy；
4. Patients with uncontrolled tumors;
5. Congestive heart failure and other comprehensive detumescence treatment contraindicated patients.

Primary outcomes:
measure: the volum of affected arm
timeFrame: at the first day and after one month
Secondary outcomes:
measure: Quality of life Core questionnaire scale -- EORTC QLQ-C30
timeFrame: at the first day and after one month
measure: Breast Cancer and Lymphedema Symptom Experience Index， BCLE-SEI
timeFrame: at the first day and after one month
Other outcomes:
Locations:
city: Hang Zhou
country: China
facility: The Second Affiliated Hospital of Zhejiang University School of Medicine
state: Zhejiang
Study officials:
References:
Clinical trial NCT02744443: Leucine Supplementation in Young Subjects Undergoing Resistance Training
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Volunteers
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2016-04-20
Enrollment: 60
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Leucine supplementation could be useful to support muscle anabolism. This study aims to investigate the effects of leucine supplementation on muscle mass and muscle strength in young subjects undergoing resistance training.


Eligibility criteria: Inclusion Criteria:

* training experience \> 12 months
* no previous use of anabolic steroids
* no diagnosed diseases or injuries at the time of recruitment
* one-maximum repetition strength (1-RM) in leg press ≥ 3.5 and ≤ 5.0 times the body weight

Exclusion Criteria:

* use of creatine or beta-alanine supplements for the last 3 months
* use of protein or aminoacids supplements for the last 1 month
* engagement in specific dietary restrictions
* engagement in competitive sports

Primary outcomes:
measure: muscle cross-sectional area
timeFrame: 12 weeks
Secondary outcomes:
measure: muscle strength
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: University of Sao Paulo
Study officials:
References:
Clinical trial NCT04648943: The Effect of Trabeculectomy & Ex-PRESS Glaucoma Drainage Implant on the Corneal Biomechanical Properties
Official title: The Effect of Antiglaucoma Procedures (Trabeculectomy vs. Ex-PRESS Glaucoma Drainage Implant) on the Corneal Biomechanical Properties
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma Eye
Keywords: glaucoma
trabeculectomy
Ex-PRESS glaucoma drainage implant
corneal hysteresis
corneal resistance factor
Lead sponsor: Democritus University of Thrace
Sponsor class: OTHER
First posted: 2020-12-02
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to look into the change of the corneal biomechanical properties in patients undergoing insertion of the Ex-PRESS mini shunt or trabeculectomy for medically uncontrolled glaucoma

Detailed description: The patients in the study were divided into two groups. In group 1 the patients had the Ex-PRESS mini shunt inserted in the operated eye and in group 2 the patients underwent standard trabeculectomy.

The corneal biomechanical properties were measured with the Ocular Response Analyzer before surgery and at 1, 6 and 12 months after surgery. The corneal biomechanical properties measured were the Corneal Hysteresis (CH) and the Corneal Resistance Factor (CRF).

The change of the CH and CRF was compared in each group before and after surgery (at the aforementioned predetermined time points) and between the two groups.

The intraocular pressure was also measured with the Goldmann applanation tonometer at the same time points and the change was compared before and after surgery in each group and between the two groups.

Eligibility criteria: Inclusion Criteria:

* Age \> 18
* Average Intraocular pressure \> 24 mmHg on at least 2 occasions 1 month before surgery
* Congenital glaucoma

Exclusion Criteria:

* Previous ocular trauma
* Previous ocular surgery other than phacoemulsification
* Previous disease of the ocular surface

Primary outcomes:
measure: Change of corneal biomechanical properties
timeFrame: 12 months
Secondary outcomes:
measure: Change of Intraocular Pressure
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
affiliation: Department of Ophthalmology, University Hospital of Alexandroupolis, Alexandroupolis, Greece
name: Georgios Labiris, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04667143: Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
Official title: A Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Retagliptin Plus Henagliflozein Added to Metformin Compared to Retagliptin or Henagliflozein in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Diabetes Mellitus, Type II
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2020-12-14
Enrollment: 760
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 2 weeks screening period, 4 weeks run-in period, 24 weeks double-blind treatment period, to evaluate the Safety and Efficacy of Retagliptin Plus Henagliflozein added to Metformin compared to Retagliptin or Henagliflozein in combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone


Eligibility criteria: Inclusion Criteria:

1. Men and women, 18-75 years old (both inclusive) at time of screening visit;
2. Subjects with T2DM with inadequate glycemic control defined as central laboratory HbA1c ≥ 7.5 and ≤ 10.5 % at the screening visit;
3. FPG ≤ 15mmol/L at the screening visit;
4. Stable metformin therapy for at least 8 weeks prior to screening at a dose ≥ 1500 mg per day;
5. 19.0\<BMI ≤ 40.0 kg/m2 at the screening visit;

Exclusion Criteria:

1. Moderate or severe impairment of renal function \[defined as eGFR\<60mL/min/1.73 m2 (estimated by MDRD);
2. Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 160 mmHg and/or diastolic blood pressure (DBP) ≥ 100 mmHg;
3. Cardiovascular diseases within 6 months of the screening visit;
4. ALT and/or AST \> 1.5 x ULN and or Total Bilirubin \> 1.2 x ULN;
5. Hemoglobin ≤ 100 g/L;
6. CK (creatine kinase) and CK-MB \> 3 x ULN;
7. Malignancy within 5 years of the screening visit (with the exception of treated basal cell or treated squamous cell carcinoma);
8. Administration of any antihyperglycemic therapy, other than metformin,within 2 months prior to screening;

Primary outcomes:
measure: Mean change from baseline in HbA1c at Week 24
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03573843: Software-guided Cognitive Stimulation to Prevents Delirium
Official title: Cognitive Stimulation Guided by a Software to Prevent Delirium in Older Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Delirium in Old Age
Keywords: Delirium
Prevention
Cognitive stimulation
Lead sponsor: University of Chile
Sponsor class: OTHER
First posted: 2018-06-29
Enrollment: 60
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is a pilot randomized controlled trial, comparing a group of older patients with standardized non-pharmacological delirium prevention plus a basic tablet versus a group with standardized non-pharmacological delirium prevention plus a tablet with a software of cognitive stimulation (PREVEDEL).

Software:It is a local development, including a interprofessional team of delirium healthcare experts, older patients and a team og engineers. The software was developed during the first year of this project and was inscribed for author rights.

Inclusion criteria: Older patients \> 65 y.o. Admitted to medicine room or intermediate care unit \> 48 hrs, and informed consent to participate.

Exclusion Criteria:Delirium positive, neuroleptic use, dementia, and non-spanish speakers.

The study was approved by ethical committee of Hospital Clinico University of Chile Standardized Non-pharmacological intervention: Health workers were previously educated in delirium, and environmental issues were implemented. This intervention coverage in nine different domains: orientation, early mobilization, environmental noise and light, sensorial deficit, sleep, hydratation, drug reduction, and family participation.

Intervention: All patients will have a tablet with or without the software PREVEDEL between 09:00-19:00 hrs.

Measures: delirium will be monitoring with CAM (Confusion Assessment Method) twice a day for 5 days.

Primary outcome: Delirium rate between both groups Secondary outcomes:Long of stay, severity od delirium, time of use of electronic device, and Barthel to discharge.


Eligibility criteria: Inclusion Criteria:

Older patients \> 65 y.o. Admitted to medicine room or intermediate care unit \> 48 hrs, and informed consent to participate.

Exclusion Criteria:

Delirium positive, neuroleptic use, dementia, and non-spanish speakers.

Primary outcomes:
measure: Difference in delirium incidence between both groups
timeFrame: 5 days
Secondary outcomes:
measure: Length of stay
timeFrame: 5 days
measure: Severity of delirium
timeFrame: 5 days
measure: Time of use of electronic device
timeFrame: 5 days
measure: Functionality at discharge.
timeFrame: 5 days
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Hospital Clínico Universidad de Chile
state: International
Study officials:
affiliation: University of Chile
name: Eduardo A Tobar, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03329443: The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography
Official title: The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Kidney Injury
IHD
Contrast-induced Nephropathy
Keywords: spironolactone
Lead sponsor: University of Baghdad
Sponsor class: OTHER
Collaborators: name: Ministry of Health-Basra Health Directorate-Al-Sader Teaching Hospital
First posted: 2017-11-06
Enrollment: 490
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: an interventional study to measure the possible effects of spironolactone ( an aldosterone antagonist) on the incidence of acute kidney injury after coronary angiography


Eligibility criteria: Inclusion Criteria:

* patients admitted to angiography unit
* over 18
* informed consent

Exclusion Criteria:

* acute renal failure before 7 days
* spironolactone contraindications
* hyperkalemia (S.K. \>5.5 mEq/L)
* documented tumor
* actively taking NSAIDs, Ciclosporin, Cisplatin,

Primary outcomes:
measure: Acute kidney injury by K-DIGO guidelines
timeFrame: 48-72 hrs
Secondary outcomes:
measure: acute kidney injury by NGAL
timeFrame: 6 hours
Other outcomes:
measure: safety outcome: serum potassium
timeFrame: 6 hrs
Locations:
city: Basrah
country: Iraq
facility: Al-Sader Teaching Hospital
Study officials:
affiliation: Baghdad University/College of Pharmacy/Department of Clinical Pharmacy
name: Alhasan Mujtaba, BCPS
role: PRINCIPAL_INVESTIGATOR
affiliation: Baghdad University/College of Pharmacy/Department of Biochemistry
name: Mohammed A Taher, Ph.D.
role: STUDY_CHAIR
affiliation: Al-Sader teaching Hospital/Basra Cardiac Center/M.D. Cardiologist
name: Mazin A Hazzaa', Ph.D.
role: STUDY_DIRECTOR
affiliation: Al-Sader teaching Hospital/Basra Cardiac Center/M.D. Cardiologist
name: Hassan M Al Rubaye, Ph.D
role: STUDY_DIRECTOR
affiliation: Al-Sader teaching Hospital/Basra Cardiac Center/M.D. Cardiologist
name: Assad H Kata, Ph.D
role: STUDY_DIRECTOR
affiliation: Head of the clinical laboratory department/ Al-Sader teaching hopital
name: Hayder K Abdullkreem, M.Sc
role: STUDY_DIRECTOR
affiliation: Al-Sader teaching Hospital/Basra Cardiac Center/M.D. Cardiologist
name: Hamid A Abdulsada, Ph.D
role: STUDY_DIRECTOR
affiliation: Al-Sader teaching Hospital/Basra Cardiac Center/M.D. Cardiologist
name: Abdul Ameer A Abdul Hameed, PH.D
role: STUDY_DIRECTOR
References:
citation: Mujtaba A, Taher MA, Hazza MA, Al-Rubaye HM, Kata AH, AbdulWahab H, AbdulBari A, AlRubay HK. The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale. Cardiol Ther. 2018 Jun;7(1):101-106. doi: 10.1007/s40119-018-0112-3. Epub 2018 May 21.
Clinical trial NCT05302843: A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors
Official title: A Phase 1，Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ascendind Doses of BPI-28592 in Subjects With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Metastasis, Neoplasm
Keywords: NTRK1/2/3, fusion
Lead sponsor: Betta Pharmaceuticals Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2022-03-31
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-labe Phase I study of BPI-28592 for the treatment of patients with solid tumors


Eligibility criteria: Inclusion Criteria:

* Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor
* At least 18 years of age
* Measurable or evaluable disease
* Adequate organ function as defined per protocol

Exclusion Criteria:

* Symptomatic or unstable brain metastases
* Pregnancy or lactation
* Other protocol specified criteria

Primary outcomes:
measure: Characterize the safety and tolerability of BPI-28592 in subjects with advanced solid tumor malignancies
timeFrame: about 20 months
measure: determine the recommended Phase II dose (RP2D) and preliminarily to develop a suitable dosing regimen
timeFrame: about 20 months
Secondary outcomes:
measure: Evaluate the pharmacokinetics of BPI-28592
timeFrame: about 20 months
measure: To determine overall response rate (ORR),calculated as the proportion of subjects with confirmed complete (CR) or partial response (PR) to BPI-28592
timeFrame: about 20 months
measure: To evaluate the duration of response (DOR) in subjects with CR or PR as best response
timeFrame: about 20 months
measure: to evaluate the disease control rate (DCR)
timeFrame: about 20 months
measure: To evaluate progression-free survival (PFS) following initiation of BPI-28592
timeFrame: about 20 months
measure: To evaluate overall (OS) following initiation of BPI-28592
timeFrame: about 20 months
Other outcomes:
Locations:
city: HangZhou
country: China
facility: Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine
state: Zhejiang
Study officials:
References: